Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for Chikungunya and Dengue Tests

The Saragene test kits approved by the CDSCO use the Company’s patented CoPrimer™ technology for the qualitative detection of these mosquito-borne viruses. According to the World Health Organization, the global incidence of dengue has grown dramatically in recent decades to become a leading cause of death in some Asian and Latin American countries, with 70% […]

Read More

House Passes $3.5 Trillion Budget, Push Medicare Drug Price Negotiations

On Tuesday, the House Democrats passed a budget blueprint on a party line vote. That blueprint allows Committees in the House to start writing the administration’s $3.5 trillion social spending or “care infrastructure” legislation. Democrats hope to move the spending measure as a reconciliation measure in the Fall. Under the reconciliation process, only 51 votes […]

Read More

COVID-19 Vaccine Policies Should Reflect the Best Available Scientific Evidence in Order to Improve Vaccine Access & Uptake

The Biotechnology Innovation Organization (BIO) believes that legislation and public health policies to address this pandemic and the use of FDA authorized and approved COVID-19 vaccines should reflect the best available scientific evidence in order to improve access to and uptake of COVID-19 vaccination. In the U.S., vaccination requirements for school entry, daycare entry, and […]

Read More

Health-Tech Company Nusano To Open an Office in Utah

Nusano, a health-tech company aiming to revolutionize uranium-free radioisotope development and production in various diagnostic and therapeutic medical applications, is opening an office in Utah. The Governor’s Office of Economic Opportunity (Go Utah) announced the news July 8, noting that the company will add up to 92 new high-paying Utah jobs in the next 15 […]

Read More

Phoenix PharmaLabs Raises More than $1 Million for Continued Development of Non-Addictive Opioids

Phoenix PharmaLabs, Inc. has completed a second successful round of financing raising $1.07 million via the Netcapital equity funding portal to continue development of two non-addictive opioids to treat acute and chronic pain. “More than a thousand investors, many of whom invested in our previous funding, participated in this offering, indicating to us they did […]

Read More

Biden Administration Recommends Policy Changes to Secure U.S. Pharmaceutical Supply Chain

In last week’s BioUtah News and Events, we highlighted the Biden Administration’s formation of a task force to address a range of supply chain issues. This week, we share the findings of the administration’s 100-day assessment of critical supply chains, undertaken pursuant to President Biden’s February 2021 “America’s Supply Chains” executive order addressing supply chain […]

Read More

Elute Receives FDA Authorization For Its First Clinical Trial Using Antibiotic Eluting Bone Void Filler

Elute has received an Investigational Device Exemption (IDE) authorization from the FDA to use its EP Granules with TobramycinTM in a pivotal clinical trial. This IDE investigates the use of a resorbable bone void filler that delivers a broad-spectrum antibiotic in the surgical treatment of bone infections following hip or knee replacements. This is the […]

Read More

House Democrats Urge HHS Secretary to Restore FDA Authority of COVID-19 Lab Developed Tests

Last August.under the Trump Administration, HHS announced that FDA would not have premarket review authority and oversight over laboratory developed tests (LDTs), including for COVID-19 tests and EUAs. Recently, House Energy and Commerce Committee Democrats sent a letter to HHS Secretary Becearra uring that he reverse the decision of the previous administration and reinstate FDA […]

Read More

Letter to Utah Congressional Delegation RE: H.R. 3, The Lower Drug Costs Now Act

Today, BioUtah, in conjunction with Centro Civico Mexicano, First Step House, International Cancer Advocacy Network, Mental Healthy FIT, Northern Utah Coalition, and Patel Family Investments, sent a letter to Utah’s congressional delegation expressing concern with the reintroduction of H.R. 3, The Lower Drug Costs Now Act. In the letter, the coalition states its concern about […]

Read More